Product class:
|
Medicinal product with marketing authorization
|
Medicinal product class:
|
Human medicine
|
Name of medicinal product:
|
CETROTIDE
|
Active substances:
|
|
ATC code:
|
H01CC02
|
Dosage form:
|
powder and solvent for solution for injection
|
Strength:
|
0,25mg
|
Legal status for supply*:
|
Subject to medicinal prescription
|
Summary of product characteristics (SPC):
|
|
Package information leaflet (PIL):
|
EST
|
Labelling:
|
|
Indication:
|
Prevention of premature ovulation in patients undergoing a controlled ovarian stimulation, followed by oocyte pick-up and assisted reproductive techniques.
In clinical trials Cetrotide was used with human menopausal gonadotropin (HMG), however, limited experience with recombinant follicule-stimulating hormone (FSH) suggested similar efficacy.
|
Safety features:
|
Yes
|
Marketing authorization holder:
|
Merck Europe B.V.
|
Marketing authorization number:
|
EU/1/99/100
|
Marketing authorization issued on:
|
August 27, 1999
|
Marketing authorization expires on:
|
Unlimited
|
Marketing authorization procedure type:
|
Centralised
|
Assessment report:
|
|
Package code
|
Name of medicinal product
|
Dosage form
|
Package
|
Legal status
|
Reimbursements
|
Reference price
|
Last imported
|
PƤritolumaa
|
Additional information
|
1043356
|
CETROTIDE
|
powder and solvent for solution for injection
|
0,25mg 1TK
|
Prescription
|
50% 100%
|
|
04.03.2024
|
|
lahusti süstlis 1 ml
|
1064696
|
CETROTIDE
|
powder and solvent for solution for injection
|
0,25mg 7TK
|
Prescription
|
|
|
|
|
lahusti süstlis 1 ml
|
Legal status for supply – medicinal product on medical prescription or not subject to medical prescription
You can download Acrobat Reader fromhere